☆ 4.7 Article

Effectiveness of COVID-19 vaccines in people living with HIV in British Columbia and comparisons with a matched HIV-negative cohort: a test-negative design

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Immunology

COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies

Manuela Di Fusco et al.

Summary: A targeted literature review summarized 10 studies conducted between December 2020 and September 2021, revealing lower effectiveness of COVID-19 vaccines among immunocompromised populations compared to the general populations. It emphasizes the need for additional protective measures for immunocompromised individuals to prevent infection and associated illness.

EXPERT REVIEW OF VACCINES (2022)

添加到收藏夹

Review Infectious Diseases

Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis

Alexandre R. Marra et al.

Summary: This study assessed the short-term effectiveness of COVID-19 vaccines among immunocompromised patients and found that they were effective against symptomatic COVID-19 infection but had lower effectiveness compared to the control group. Further research is needed to understand the discordance between antibody production and protection against symptomatic COVID-19 infection.

JOURNAL OF INFECTION (2022)

添加到收藏夹

Article Immunology

Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States

Mark W. Tenforde et al.

Summary: From March to May 2021, full vaccination using authorized mRNA products was associated with 87.1% protection against COVID-19 hospitalization among US adults, with lower effectiveness in adults with immunosuppression compared to those without. Vaccination was beneficial for patients with immunosuppression, but the effectiveness was lower in this population.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Immunology

Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada

Danuta M. Skowronski et al.

Summary: Vaccine effectiveness estimated in British Columbia, Canada showed that one dose of mRNA vaccine reduced the risk of SARS-CoV-2 infection in adults >= 70 years old by about two-thirds, with protection only minimally reduced against Alpha and Gamma variants.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Immunology

Covid-19 vaccine immunogenicity in people living with HIV-1

Lauriane Nault et al.

Summary: This study evaluated the immunogenicity of an mRNA anti-SARS-CoV-2 vaccine in HIV-positive individuals. The results showed that HIV-positive individuals with CD4 counts over 250 cells/mm(3) had a similar antibody response to the general population. However, HIV-positive individuals with the lowest CD4 counts (<250 cells/mm(3)) had a weaker response and may require a booster dose. Increasing age was independently associated with decreased immunogenicity.

VACCINE (2022)

添加到收藏夹

Article Immunology

Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy

Zabrina L. Brumme et al.

Summary: This study suggests that people living with HIV who have well-controlled viral loads and CD4+ T-cell counts in a healthy range generally have strong humoral responses to dual COVID-19 vaccination. Factors such as age, comorbidities, vaccine brand, response durability, and the emergence of new SARS-CoV-2 variants will impact when individuals with HIV will benefit from additional vaccine doses.

NPJ VACCINES (2022)

添加到收藏夹

Article Medicine, General & Internal

Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes

Sarah A. Buchan et al.

Summary: A study conducted in Ontario, Canada, found that the incidence of SARS-CoV-2 infection, including among individuals who have received 2 doses of COVID-19 vaccine, increased significantly following the emergence of the Omicron variant. The study estimated the effectiveness of 2 or 3 doses of COVID-19 vaccine against symptomatic infections and severe outcomes associated with Omicron and Delta variants. The results showed that the estimated effectiveness decreased for symptomatic Delta infection after the second dose, but increased to 97% after the third dose. For symptomatic Omicron infection, the estimated effectiveness was relatively low, but increased to 61% after the third dose. The estimated effectiveness against severe outcomes was high after the third dose for both variants.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Medicine, General & Internal

Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy

Vladimir A. Gushchin et al.

Summary: This paper provides a preliminary assessment of the effectiveness of Sputnik V vaccine in HIV-positive patients on antiretroviral therapy. The study suggests that Sputnik V immunization has epidemiological efficiency in preventing hospitalization and moderate or severe disease in HIV-positive individuals, including those infected with the delta variant of SARS-CoV-2.

ECLINICALMEDICINE (2022)

添加到收藏夹

Article Immunology

Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019

Dima Dandachi et al.

Summary: The study found that people living with HIV have a higher risk of severe outcomes from COVID-19, especially those with older age, chronic lung disease, hypertension, and lower CD4 cell counts. Antiretroviral therapy and viral suppression did not have a significant impact on the outcomes examined.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa

Andrew Boulle et al.

Summary: In South Africa, living with HIV and having current tuberculosis were independently associated with increased COVID-19 mortality. These findings highlight the impact of these two diseases on COVID-19 risk and demonstrate the associations between age, sex, and other comorbidities with COVID-19 mortality.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

People living with HIV easily lose their immune response to SARS-CoV-2: result from a cohort of COVID-19 cases in Wuhan, China

Yanbin Liu et al.

Summary: In COVID-19 patients, individuals living with HIV had a lower and shorter duration of IgG seroconversion for SARS-CoV-2 compared to HIV-naive individuals.

BMC INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

Krishnan Bhaskaran et al.

Summary: This study found that people living with HIV in the UK are at a higher risk of COVID-19 mortality compared to those without HIV. Even after adjusting for age, sex, ethnicity, and a range of comorbidities, the elevated risk remained significant, especially among individuals of Black ethnicity. Targeted policies should be considered to address this increased risk in the evolving pandemic response.

LANCET HIV (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study

Erjia Ge et al.

Summary: The study revealed that comorbidities play a significant role in the mortality and severity of COVID-19 patients, with a higher number of comorbidities associated with increased risks. Specifically, comorbidities were found to have a greater impact on younger individuals, emphasizing the importance of prioritizing vaccination for younger populations with multiple comorbidities.

PLOS ONE (2021)

添加到收藏夹

Article Immunology

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Daniel K. Nomah et al.

Summary: This study assessed factors associated with SARS-CoV-2 diagnosis and severe outcomes among people living with HIV. The findings showed that age, immigrant status, sexual orientation, chronic comorbidities, and other factors were associated with SARS-CoV-2 diagnosis and severe outcomes. Participants with detectable HIV viraemia, chronic comorbidities, and certain subpopulations were at increased risk of severe outcomes from COVID-19, highlighting the importance of prioritizing these groups in clinical management and vaccination programs.

LANCET HIV (2021)

添加到收藏夹

Article Immunology

Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data

Xueying Yang et al.

Summary: The study using N3C data in the US found that individuals with HIV infection have higher odds of COVID-19 death and hospitalisation, but lower odds of mild or moderate COVID-19. Factors such as older age, male gender, and specific racial/ethnic groups may exacerbate the risk of adverse COVID-19 outcomes among people with HIV.

LANCET HIV (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis

Paddy Ssentongo et al.

Summary: Susceptibility to SARS-CoV-2 infection and mortality risk are higher among people living with HIV/AIDS compared to HIV-negative individuals. The beneficial effects of antiretroviral therapy in reducing infection and mortality risks for COVID-19 in PLWHA remain inconclusive. Prioritizing SARS-CoV-2 vaccination for persons with HIV is recommended to mitigate the increased risk associated with HIV infection.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Infectious Diseases

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

Itzchak Levy et al.

Summary: The Pfizer-BioNTech BNT162b2 mRNA vaccine demonstrates immunogenicity and safety in people living with human immunodeficiency virus type 1 (PLWH) who are receiving antiretroviral therapy with unsuppressed CD4 count and suppressed viral load. Adverse events are mainly mild, such as pain at the injection site, fatigue, and headache. Immune response to the vaccine is strong, with high levels of anti-RBD-IgG and neutralizing antibodies observed in both PLWH and immunocompetent health-care workers.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

Hannah Chung et al.

Summary: The study demonstrates that two doses of mRNA covid-19 vaccines are highly effective against symptomatic infection and severe outcomes. However, the effectiveness of one dose is lower, particularly for older adults shortly after the first dose. For adults aged >=70 years, vaccine effectiveness estimates were observed to be lower for intervals shortly after one dose but were comparable to those for younger people for all intervals after 28 days.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Evaluating the Utility of Coarsened Exact Matching for Pharmacoepidemiology Using Real and Simulated Claims Data

John E. Ripollone et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2020)

添加到收藏夹

Review Public, Environmental & Occupational Health

The Use of Test-negative Controls to Monitor Vaccine Effectiveness A Systematic Review of Methodology

Huiying Chua et al.

EPIDEMIOLOGY (2020)

添加到收藏夹

Article Substance Abuse

Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets

Naveed Zafar Janjua et al.

INTERNATIONAL JOURNAL OF DRUG POLICY (2018)

添加到收藏夹

Article Public, Environmental & Occupational Health

Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness

Sheena G. Sullivan et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked Participants

Naveed Zafar Janjua et al.

PLOS ONE (2016)

添加到收藏夹

Article Infectious Diseases

The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials

G De Serres et al.

Eurosurveillance (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Application and Validation of Case-Finding Algorithms for Identifying Individuals with Human Immunodeficiency Virus from Administrative Data in British Columbia, Canada

Bohdan Nosyk et al.

PLOS ONE (2013)

添加到收藏夹

Article Immunology

The test-negative design for estimating influenza vaccine effectiveness

Michael L. Jackson et al.

VACCINE (2013)

添加到收藏夹

Article Statistics & Probability

Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research

Peter C. Austin

COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.